Skip to main content
PTKFY logo

PT Kalbe Farma Tbk (PTKFY) Stock Price & Analysis

PT Kalbe Farma Tbk (PTKFY) — price $8.36 (0.00%), as of the Nov 19, 2026 trading session; market cap $1.89B.

Educational signal · not a buy or sell recommendation · How to read this

$8.36 $0.00 (0.00%) Market Cap $1.89B

PT Kalbe Farma Tbk · PTKFY

PT Kalbe Farma Tbk. is a leading Indonesian pharmaceutical company specializing in a diverse range of healthcare products, including prescription medications, over-the-counter drugs, and nutritional products.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • OGN · Organon & Co. · 37 /100
  • GRFS · Grifols, S.A. · 60 /100
  • BIIB · Biogen Inc. · 37 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$8.36
Change on the day0.00%
52-week range$7.21 – $16.36
Market capitalisation$1.89B—
Price / earnings (trailing)9.61
Shares traded on the day2.4K

Price & events

Other perspectives

Council score for PT Kalbe Farma Tbk (PTKFY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 6, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Neutral
Revenue Growth Neutral
Debt/Equity Strong
ROE Moderate
Gross Margin Neutral

Read on: May 2, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On May 2, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is PT Kalbe Farma Tbk (PTKFY), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. PT Kalbe Farma Tbk (PTKFY) is the company analyzed here. It employs 12,835 people and is led by Bernadette Ruth Irawati Setiady. In Q3 FY2026 it reported revenue of IDR 9484.30B and net income of IDR 816.49B. The market values it at $1.89B.

2 · Latest results

What do the latest results show for PT Kalbe Farma Tbk (PTKFY)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of IDR 9484.30B.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026IDR 9484.30BIDR 816.49BIDR 3566.00 (diluted)
Q2 FY2026IDR 9800.45BIDR 890.54BIDR 3936.00 (diluted)
Q1 FY2026IDR 9820.13BIDR 1044.00BIDR 4586.00 (diluted)
Q4 FY2025IDR 9336.25BIDR 1033.65BIDR 4562.00 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for PT Kalbe Farma Tbk (PTKFY)?

Short answer · as of

The distress and quality screens read Altman Z 3.31 · Piotroski F 6. Trailing ratios: ROE 15.5% · ROA 11.3% · current ratio 3.50 · earnings yield 10.6% · free-cash-flow yield 8.3%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held PTKFY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported PTKFY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Investor Questions: PTKFY Stock

These answers are editorial: 1 of these 8 answers is drawn from the PTKFY research dossier (written Jun 15, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is PTKFY a good stock to buy?

Stock Expert AI does not rate PTKFY buy, sell or hold. PT Kalbe Farma Tbk has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the PTKFY stock price today?

The last price recorded for PT Kalbe Farma Tbk (PTKFY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for PTKFY?

Main risks for PT Kalbe Farma Tbk. include currency fluctuations that may affect the valuation of its ADR, regulatory changes that could impact product approvals, and economic downturns that might reduce consumer spending on healthcare products.

What are the key factors to evaluate for PTKFY?

Evaluate PTKFY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Kalbe Farma's potential to innovate in this space could provide new revenue opportunities and enhance patient engagement. Not financial advice.

How frequently does PTKFY data refresh on this page?

PTKFY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven PTKFY's recent stock price performance?

PT Kalbe Farma Tbk (PTKFY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading market position in Indonesia's pharmaceutical sector. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PTKFY overvalued or undervalued right now?

The trailing P/E of PT Kalbe Farma Tbk (PTKFY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research PTKFY before investing?

Before investing in PT Kalbe Farma Tbk (PTKFY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.